Group items tagged

New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division Haleon. After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain around U.S. litigation over heartburn drug Zantac. Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.

Major Highlights of the Sugar Beet Seeds Market report study: A detailed look at the global Sugar Beet Seeds Industry The report analyzes the global Sugar Beet Seeds market and provides its stakeholders with significant actionable insights The report has considered all the major developments in the recent past, helping the users of the report with recent industry updates The report study is expected to help the key decision-makers in the industry to assist them in the decision-making process The study includes data on market intelligence, changing market dynamics, current and expected market trends, etc. The report comprises an in-depth analysis of macroeconomic and microeconomic factors affecting the global Sugar Beet Seeds market Market Ecosystem and adoption across market regions Major trends shaping the global Sugar Beet Seeds market Historical and forecast size of the Sugar Beet Seeds market in terms of Revenue (USD Million) Recent industry development and consumer preference trends Competitive Landscape and player positioning analysis for the global Sugar Beet Seeds market Key products and solution offerings by major players and business strategies adopted Recommendations for new market entrants and current players operating in the market space Analysis of niche and potential segments (type, application, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations Get FREE PDF Copy @ https://www.marketresearchstore.com/sample/sugar-beet-seeds-market-794502?utm_source=diigo.com-VPL&utm_medium=Varsha

It's time for pharmacists to get their technology forecasting hats on and be selective in choosing digital technologies, commented Prof James Woudhuysen, of London South Bank University, at the National Pharmacy Association (NPA) Conference, Pharmacy Odyssey, held on Thursday (13 October). In a session on 'Healthcare in tomorrow's digital environment', hosted by Fergus Walsh, Prof Woudhuysen opined that digitisation has its merit, but it's quite tricky, and slower than we imagine. "Mechanisation has a digital component that we can look to as a way out of the gloom of the moment. And in dispensing, labelling, prescribing, and many other features of the conventional retail pharmacist, there's a lot that could be done for productivity and automation," he said. Replying to a question on 'where are we at the digital front now and where can it go', Woudhuysen replied: "It's taken 20 years for the electronic prescription. It was Tony Blair, who wanted every prescription electronic. The mishaps on repeat prescriptions and all the rest of it are still quite intense. So, we need to remember that electronics is only as clever as software and then human input into it. There're still many mistakes.

The orthopedic large joint reconstruction device market includes hip reconstruction devices, knee reconstruction devices and bone cements used to help adhere the implants to bone. Large joint arthroplasty experienced a continued increase in demand in 2012, attributed to the aging Brazilian population and an increased number of patients able to afford these procedures. Procedure growth will rise over the forecast period as older patients are no longer able to postpone elective joint replacement. Hip reconstruction market growth will continue to outpace knee reconstruction market growth throughout the forecast period. Both the knee and hip markets experienced a steep increase in growth in 2012, as more orthopedic products continued to be introduced into Brazil. Unit volumes will continue to grow steadily over the forecast period due to the growing demand for arthroplasty.

The U.S. Food & Health Supplement Stores Industry-Industry & Market Report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2013 current and 2014 forecast estimates on the size of the industry (sales, establishments, employment) nationally and for all 50 U.S.

Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in US community and regional blood centers, hospitals, commercial laboratories, and plasma fractionation facilities.

Black Haircare Market Report covers key strategic developments of the market including acquisitions & mergers, new type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the black haircare market on a global and regional basis. To give the users of this report a comprehensive view on the black haircare market competitive landscape and analysis of Porter's Five Forces model for the market are included in the report. The study encompasses market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

British pharmaceutical giant GlaxoSmithKline beat first-quarter sales and earnings forecasts on Wednesday (April 27), helped by demand for its Covid-19 therapy and shingles vaccine, as the company moves towards the July separation of its consumer health business. Profit after tax jumped 68 percent to £1.8 billion ($2.3 billion, 2.1 billion euros) compared with the start of 2021. Sales climbed 32 percent to almost £9.8 billion. "We have delivered strong first-quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth," chief executive Emma Walmsley said in the earnings statement. "Our results reflect further good momentum across speciality medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress." The shingles vaccine generated £698 million in quarterly sales, beating analyst estimates of 528 million. Walmsley is seeking to reshape GSK after facing fierce investor criticism over the company's delay in producing Covid jabs and treatments.

Alphega Pharmacy Oncology Support Programme allows community pharmacists from six European countries to enhance support and guidance they provide to cancer patients. The programme aims to help upskill pharmacists and their teams to provide more expert advice to patients living with cancer, raising their profile in the community as key healthcare providers. Enhancing knowledge amongst community pharmacists about cancer treatment and its side effects is vital as cancer cases are set to increase if current trends continue. The programme covers practical help topics, such as oral care, nutrition advice and skin, hair and nail care among others, helping patients to get more of the support they need because community pharmacists are easily accessible, rather than needing to book a GP or consultant appointment. With rates of cancer forecast to rise throughout Europe , and cancer patients likely on average to visit hospital less often, community pharmacists are well-placed to look to support cancer patients with managing the side-effects of their treatment.

A new study published in The Lancet has revealed that a total of 1.7 million people could be living with dementia in England and Wales by 2040. The research highlighted increasing numbers of people who will suffer from Alzheimer's. The disease would massively increase the burden on the healthcare system. The research was led by University of College London (UCL). Lead researcher, Dr Yuntao Chen said, "It is shocking to think that the number of people living with dementia by 2040 may be up to 70 per cent higher than if dementia incidence had continued to decline. "Not only will this have a devastating effect on the lives of those involved but it will also put a considerably larger burden on health and social care than current forecasts predict.

American biotechnology company Novavax said on Monday (February 28) it would pursue full approval of its Covid-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022. "We expect to gain additional authorizations where we have already filed, including in the US. We will pursue full approval of our vaccine including filing our BLA (biologics license application), in the second half of 2022," CEO Stanley Erck said during a post-earnings call. Novavax late last month filed for emergency use authorization of the shot in U.S. adults, a much-awaited step following months of struggles with development and manufacturing problems. Novavax said it has completed delivery of around nine million vaccine doses to Indonesia, 6 million to Australia and two million to South Korea and expects to supply 69 million doses to Europe in the first half of this year.

Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83. Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade. "The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric. Biohaven forecast Nurtec sales of $825 million to $900 million in 2022. Pfizer said it expects the pills to eventually overtake the shots.

The Department of Health and Social Care (DHSC) has proposed a 2.8% pay uplift for NHS Agenda for Change (AfC) staff, including hospital pharmacists, for the 2025/2026 pay round. This recommendation was detailed in the DHSC's submission to the NHS Pay Review Body (NHSPRB), which described the figure as "a reasonable amount to have set aside based on the macroeconomic data and forecasts and taking into account the fiscal and labour market context." NHS England also supported the 2.8% pay increase, stating that its proposal reflects "the likely NHS budget from discussions to date with DHSC and what was set out by HM Treasury in the Autumn Budget 2024." "We propose to set allocations for NHS planning on the basis of a 2.8% pay settlement. Every 0.5% increase above that costs around £700m; which is the equivalent to around 2% of elective activity (greater than 300k completed patient pathways)," it added. However, Unite the Union, representing NHS staff, condemned the DHSC's recommendation, called the proposed increase "an insult."

The 2025/26 pharmacy contract consultation will include a review of the medicine margin and reimbursement arrangements, health and care minister Stephen Kinnock has confirmed. Kinnock made this statement in response to a written question from Nick Timothy, Conservative MP for West Suffolk, who asked the secretary of state for health and social care, if he will review the reimbursement system for pharmacies and GP practices dispensing medicines. Kinnock stated that consultation with Community Pharmacy England (CPE) for the 2025/26 Community Pharmacy Contractual Framework (CPCF) has started and will include "reviewing the allowance for medicine margin as part of funding, and any further changes to the reimbursement arrangements." However, he clarified that there are currently no plans to review the reimbursement system for general practices (GPs) dispensing medicines. Kinnock said: "Dispensing practices receive a dispensing fee, approximately £2.00 to £2.30 per item, which is intended to cover dispensing costs. "This fee is calculated based on forecasted volumes of prescriptions to be dispensed and the size of the funding envelope, according to a methodology agreed by the Department, the General Practitioners Committee (GPC), NHS Employers, and the Welsh Government."

Healthcare is one of the most crucial sectors in the UK accounting for over £290 billion, around 10% of the GDP for the entire country. Despite this, however, many businesses operating in the healthcare sector are currently in favour of an urgent cash injection from the government. The figures make for sobering reading with over 65% of pharmacies operating at a loss and a bleak forecast that one in six might shut their doors for good within the next year. Business costs have soared in the last two years and combined with a funding cut of around 30% in real terms over the last decade this has left many pharmacies struggling to make ends meet. In real terms, these issues affect those who we wish to help the most - our patients. As the expenditure rises, income doesn't always follow meaning that pharmacy staff have to work even harder. However, despite their best efforts they report that this has an impact on some of the valuable face time that they can give to their patients. Longer prescription dispensing times have been an issue across the board as this then creates a domino effect on responding to patient enquiries. This then means that when a patient is actually in store there is less time for a pharmacist to spend with a patient discussing their health issues.

The global molecular diagnostics market is witnessing a period of profound growth. The growth is coming from different regions and markets. The next five years will witness significant developments in molecular diagnostics such as automation, as well as introduction of a wide range of new products. Molecular Diagnostics involves multiple technologies to identify genetic variations in individual patients. These technologies include PCR, FISH, hybrid capture, sequencing and microarrays.

Hair Care in Slovenia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

Ear Care in Croatia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

Oral Care in Saudi Arabia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

Market structure details the player categories, key players' presence across products and end user segments. Market practices include understanding the Indian Pharmaceutical business, market trends, distribution practices and pricing.The report also provides a snapshot of key competition, past market trends with forecast over the next 5 years, anticipated growth rates and the principal factors driving and impacting growth.